Riskpilot← Back to searchSign inGet full accessBlue Cell Therapeutics ApS
APSActiveCVR 39981610Ole Maaløes Vej 3, 3.Research and experimental development on natural sciences and engineering · NACE 7210Est. 201811 employees
Revenue 2024
DKK -3,1M
+312% vs 2023
EBITDA margin
569.3%
+3% vs 2023
Equity ratio
92.7%
Financial strength
Net profit 2024
DKK -15,2M
+1% vs 2023
| Revenue | DKK -3,1M | +312% |
| EBITDA | DKK -17,4M | +3% |
| Net profit | DKK -15,2M | +1% |
| Total assets | DKK 14,1M | +39% |
| Equity | DKK 13,1M | +56% |
| Employees | 11 | — |
Legal name
Blue Cell Therapeutics ApS
CVR number
39981610
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
28. oktober 2018
Share capital
DKK 53.745
Employees
11 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den administrerende direktør, den administrerende direktør i forening
med et bestyrelsesmedlem eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive virksomhed med udvikling, behandling og kommercialisering af stamceller og hermed efter ledelsens skøn beslægtet virksomhed.
Address
Ole Maaløes Vej 3, 3.
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 0 | -2.944 | -844 | 852 | -742 | -3.053 |
| Staff expenses | -0 | -12.007 | -8.474 | -11.643 | -14.196 | -12.786 |
| EBITDA | 0 | -14.951 | -15.163 | -14.527 | -17.924 | -17.378 |
| Depreciation & amort. | -0 | -0 | -219 | -274 | -335 | -163 |
| EBIT | 0 | -14.951 | -15.382 | -14.800 | -18.259 | -17.541 |
| Net financials | 0 | -41 | -51 | -64 | -4 | -10 |
| Profit before tax | 0 | -14.992 | -15.433 | -14.865 | -18.262 | -17.551 |
| Tax | -0 | -965 | -1.192 | -2.295 | -2.974 | -2.361 |
| Net profit | 0 | -14.027 | -14.241 | -12.570 | -15.288 | -15.190 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 2 | 13.504 | 14.005 | 10.625 | 10.159 | 14.124 |
| Equity | 2 | 9.776 | 12.481 | 9.911 | 8.419 | 13.094 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 3.728 | 1.524 | 713 | 1.740 | 1.030 |
| Total debt | 0 | 3.728 | 1.524 | 713 | 1.740 | 1.030 |
EBITDA margin
-1737789400.0%
This company
15.8%
Market median
-10998667189% vs market
20192024
Equity ratio
92.7%
This company
38.2%
Market median
+143% vs market
20192024
Return on equity
-116.0%
This company
18.4%
Market median
-730% vs market
20192024
Net profit margin
-1518985000.0%
This company
8.1%
Market median
-18752901335% vs market
20192024
Asset turnover
-0.22×
This company
1.12×
Market median
-120% vs market
20192024
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-10-28 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TT Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
SP Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
SPSheikh Holding ApS | Company | 33.3% | 33.3% | 2024 |
ANDRÉ ROGACZEWSKI HOLDING II ApS | Company | 33.3% | 33.3% | 2024 |
SEIER CAPITAL A/S | Company | 5.0% | 5.0% | 2024 |
| Individual | 5.0% | 5.0% | 2019 | |
TTH HOLDING ApS | Company | 5.0% | 5.0% | 2020 |
SPLUSH GROUP ApS | Company | 5.0% | 5.0% | 2019 |
SHEIKH HOLDING ApS | Company | 50.0% | 50.0% | 2019 |
REGTISS ApS | Company | 5.0% | 5.0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ANDRÉ ROGACZEWSKI HOLDING II ApS
Blue Cell Therapeutics ApS Board members of Blue Cell Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Tofte Hansen | Chief Executive Officer | 0 companies |
| Søren Paludan Sheikh | Chief Executive Officer | 0 companies |
| Sebastian Wehle | Board of Directors | 0 companies |
| André Rafal Rogaczewski | Board of Directors | 0 companies |
| Casper Tind Hansen | Board of Directors | 0 companies |
| Michael Ulveman | Board of Directors | 0 companies |
| Anella Rogaczewski | Board of Directors | 0 companies |
| Anders Vadsholt | Board of Directors | 0 companies |
| Olav Hellebø | Chairman | 0 companies |
| Ole Vahlgren | Board of Directors | 0 companies |